ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,035.69
0.00%
Dow Jones
37,815.92
0.00%
US Dollar vs MXN
17.08272
-0.41%
Brent Oil
85.235
-0.77%
Bitcoin
58,137.71
-4.06%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Legend Biotech Corporation (LEGN)

  7. Legend Biotech Corporation (LEGN) Noticias

LEGN Legend Biotech Corporation

43.74
0.00 (0.00%)
Pre Mercado
Última actualización: 06:00:01
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Legend Biotech Corporation LEGN NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 43.74 06:00:01
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
43.74
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
22/4/202412:05BWCARVYKTI® (ciltacabtagene autoleucel) Approved by the..
11/4/202407:00BWLegend Biotech to Host Investor Conference Call on First..
05/4/202422:30BWLegend Biotech’s CARVYKTI® (ciltacabtagene autoleucel)..
19/3/202407:30BWLegend Biotech Announces Publication of Inaugural..
15/3/202414:15BWCARVYKTI® (ciltacabtagene autoleucel) Receives..
11/3/202406:52EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/3/202406:00BWLegend Biotech Reports Fourth Quarter and Full Year 2023..
11/3/202405:39IHMARKETNEWSU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s..
28/2/202417:46EDGAR2Form 144/A - Report of proposed sale of securities: [Amend]
27/2/202418:47EDGAR2Form 144 - Report of proposed sale of securities
23/2/202412:10EDGAR2Form 144 - Report of proposed sale of securities
23/2/202406:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/2/202406:15BWLegend Biotech Announces Positive CHMP Opinion for CARVYKTI®..
14/2/202419:34EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202407:00BWLegend Biotech to Host Investor Conference Call on Fourth..
23/1/202408:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/1/202406:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/1/202415:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/1/202410:28BWLegend Biotech Announces Closing of License Transaction for..
03/1/202407:30BWLegend Biotech Announces Closing of License Transaction for..
02/1/202407:30BWLegend Biotech to Participate in the 42nd Annual J.P. Morgan..
27/12/202309:00EDGAR2Form 144 - Report of proposed sale of securities
22/12/202314:38EDGAR2Form 144 - Report of proposed sale of securities
22/12/202314:21EDGAR2Form 144 - Report of proposed sale of securities
21/12/202316:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202315:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/12/202313:31EDGAR2Form 144 - Report of proposed sale of securities
11/12/202318:30BWPatient-Reported Outcomes from the CARTITUDE-4 Study Showed..
20/11/202305:25IHMARKETNEWSMonday’s Wall Street Highlights: GM, Microsoft, Citigroup,..
20/11/202305:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/11/202305:00BWLegend Biotech Reports Third Quarter 2023 Results and Recent..
13/11/202308:16DJNLegend Biotech Subsidiary in License Agreement With Novartis
13/11/202307:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/11/202307:30BWLegend Biotech Announces Exclusive, Global License Agreement..
07/11/202307:30BWLegend Biotech to Host Investor Conference Call on..
02/11/202308:17BWLegend Biotech to Showcase Leadership in Multiple Myeloma..
17/10/202316:39EDGAR2Form 144 - Report of proposed sale of securities
17/10/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/10/202316:20EDGAR2Form 144 - Report of proposed sale of securities
27/9/202311:02EDGAR2Form 144 - Report of proposed sale of securities
25/9/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/9/202315:20EDGAR2Form 144 - Report of proposed sale of securities
22/9/202315:10EDGAR2Form 144 - Report of proposed sale of securities
18/9/202315:41EDGAR2Form 144 - Report of proposed sale of securities
28/8/202309:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/8/202315:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/8/202305:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/8/202305:00BWLegend Biotech Reports Second Quarter 2023 Results and..
03/8/202307:30BWLegend Biotech to Host Investor Conference Call on..
20/7/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..

Su Consulta Reciente

NASDAQ
LEGN
Legend Biotech
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados